## EU Pharma Data Rigging: Whistleblower Reveals 'Controlled' Trial Results
Sources within the EU pharmaceutical regulatory landscape point to a persistent issue of data manipulation in clinical trials submitted for drug approval. A recent anonymous tip, corroborated by internal audit trails from a mid-sized German contract research organization (CRO), suggests that certain adverse event data for a widely prescribed cardiovascular drug were systematically downplayed or omitted to meet efficacy thresholds.  The CRO, known for its work with several major European pharma players, allegedly employed a 'data smoothing' technique, masking statistically significant negative outcomes. This practice, if widespread, poses a severe risk to patient safety across the continent, as regulatory bodies like the EMA may be approving drugs based on incomplete or misleading information. The implications for public health and trust in the regulatory process are profound.
---
- **Source**: 
- **Sector**: The Lab
- **Tags**: pharma fraud, eu, data manipulation, clinical trials
- **Credibility**: unverified
- **Published**: 2026-02-28 13:27:30
- **ID**: 780
- **URL**: https://whisperx.ai/en/intel/780